Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: Randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone

British Journal of Rheumatology

Volumn 37, Issue 10, 1998, Pages 1102-1109

  Verhoeven, A C ^a   Bibo, J C ^a   Boers, M ^b   Engel, G L ^a   Van Der Linden, Sj ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Combined treatment; Cost effectiveness; Cost utility analysis; DMARDs; Early rheumatoid arthritis; Glucocorticoids; Methotrexate; Prednisolone; Randomized double blind trial; Sulphasalazine

Indexed keywords

METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; HOME CARE; HOSPITAL COST; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JOINTS; MALE; METHOTREXATE; MIDDLE AGED; PREDNISOLONE; SEVERITY OF ILLNESS INDEX; SULFASALAZINE; TREATMENT OUTCOME;

EID: 0031785631     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Gordon DA, Hastings DE. Rheumatoid arthritis. Clinical features: early, progressive and late disease. In: Klippel JH, Dieppe PA, eds. Rheumatology. St Louis: Mosby, 1994:1-14.
2. Wolfe F, Hawley DJ, Cathey MA. Clinical and health status measures over time: prognosis and outcome assessment in rheumatoid arthritis. J Rheumatol 1991;18:1290-7.
3. McIntosh E. The cost of rheumatoid arthritis. Br J Rheumatol 1996;3:781-90.
4. Bosi Ferraz M, Maetzel A, Bombardier C. Critical appraisal of economic evaluation published in the field of rheumatology and related disciplines. Arthritis Rheum 1997;40:1587-93.
5. Boers M, Verhoeven AC, Markusse HM et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulpha-salazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
6. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
7. Smythe HA, Helewa A, Goldsmith CH. 'Independent assessor' and 'pooled index' as techniques for measuring treatment effects in rheumatoid arthritis. J Rheumatol 1977;4:144-52.
8. Centraal Economisch Plan. The Hague: SDU, 1996.
9. Gabriel SE, Crowson CS, Campion ME, O'Fallon WM. Direct medical costs unique to people with arthritis. J Rheumatol 1997;24:719-25.
10. Rutten FFH, van Ineveld BM, van Ommen R, van Hout BA, Huijsman R. Directe kosten binnen de gezondheidszorg. In: Kostenberekening bij gezondheidszorg-onderzoek; richtlijnen voor de praktijk. Utrecht: van Arkel, 1993.
11. Tugwell P, Bombardier C, Buchanan WW, Goldsmith CH, Grace E, Hanna B. The MACTAR patient preference disability questionnaire: an individualized functional priority approach for assessing improvement in physical disability in clinical trials in rheumatoid arthritis. J Rheumatol 1987;14:446-51.
12. van der Heijde DMFM, van Riel PL, Nuver-Zwart IH, Gribnau FW, van de Putte LBA. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;i:1036-8.
13. van Leeuwen MA, van der Heijde DMFM, van Rijs wijk MH et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol 1994;21:425-9.
14. Fries JF, Spitz PW, Young DY. The dimensions of health outcome: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
15. Siegert CEH, Vleming LJ, Vanderbroucke JP, Cats A. Measurement of disability in Dutch rheumatoid arthritis patients. Clin Rheumatol 1984;3:305-9.
16. Bennett K, Torrance GR, Tugwell P. Methodological challenges in the development of utility measure of health-related quality of life in rheumatoid arthritis. Control Clin Trials 1991;12 (suppl.):118-28.
17. Bakker CH, Rutten-van Mölken MPMH, van Doorslaer EKA, Bennet K, van der Linden S. Health related utility assessment by rating scale and standard gamble in patients with ankylosing spondylitis or fibromyalgia. Patient Educ Counsel 1993;20:145-52.
18. American College of Rheumatology ad hoc committee on clinical guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996;39:723-31.
19. Goossens MEJB, Rutten-van Mölken MPMH, Leidl RMJ, Bos SGPM, Vlaeyen JWS, Teeken-Gruben NJG. Cognitive-educational treatment of fibromyalgia: Randomized clinical trial. II Economic evaluation. J Rheumatol 1996;23:1246-54.
20. Lanes SF, Lanza LL, Radensky PW et al. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting. The importance of drug and surgery costs. Arthritis Rheum 1997;40: 1475-81.
21. Vliet Vlieland TPM, Zwinderman AH, Vandenbroucke JP, Breedveld FC, Hazes JMW. A randomised clinical trial of in-patient multidisciplinary treatment versus routine outpatient care in active rheumatoid arthritis. Br J Rheumatol 1996;35:475-82.